This article is more than 5 years old. Information may no longer be current.

Additional manufacturing site for Akorn's IC-Green approved by FDA

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BUFFALO GROVE, Ill. — Akorn has received approval from the U.S. Food and Drug Administration for an alternate site for manufacturing IC-Green, the company announced in a press release. Akorn will begin customer shipments immediately, the release said.

Currently, the customer order backlog for IC-Green is approximately $3 million. Of this, $1.8 million will ship and bill in the third quarter, with the remaining $1.2 million to be fulfilled in the fourth quarter, according to the release.

"Akorn regrets any inconvenience this drug shortage has created and is pleased to relaunch IC-Green into the marketplace," the release said.